Reviewer's report

Title: Intratumoral heterogeneity impacts the response to anti-neu antibody therapy

Version: 4 Date: 14 April 2014

Reviewer: Lucas Abrahao-Machado

Reviewer's report:

1) Major Compulsory Revisions

The assessment of HER2 status either by immunohistochemistry or by FISH is essential in this study. To demonstrate the intratumoral heterogeneity, which is in my opinion the most important subject of this paper, the authors could use immunohistochemistry, the simplest method and very accurate. I think it is not very clear how intratumoral heterogeneity of HER2 was assessed.

2) Minor Essential Revisions

The introduction is confused. The term antibody is equivocal since it can be used to refer both as immunohistochemical antibody and as the drug. I suggest replacing the word antibody for drug.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests.